Scilex, a Sorrento Company, Announces Initiation of a Phase

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and...

Related Keywords

Florida ,United States ,California ,San Diego ,Palo Alto ,Americans ,Jaisim Shah ,Alan Miller ,Dmitri Lissin ,Sorrento Therapeutics Inc Nasdaq ,Department Of The Institute For Health Metrics ,Scilex Holding Company ,Drug Administration ,Vickers Vantage Corp ,Nasdaq ,Brand Essence Research ,Sorrento Therapeutics Inc ,Vickers Venture Fund Vi Pte Ltd ,University Of Washington ,Sorrento Company ,Vickers Venture Fund Vi Plan Pte Ltd ,Pivotal Trialc Le Ar Program ,Holding Company ,Sorrento Therapeutics ,Chief Medical Officer ,Interventional Pain Management ,Coastal Spine ,Pain Center ,Fernandina Beach ,Chief Executive Officer ,Health Metrics ,Vickers Vantage ,Vickers Venture Fund ,Pte Ltd ,Lumbar Epidural Analgesia ,Text View ,Registration Statement ,Nasdaq Srne ,Nc ,